Bioton S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2004-08-02
Share capital
8,586,420.00 PLN
Activity description

Bioton is a Polish biotechnology company that specializes in the development and production of biopharmaceuticals, particularly insulin for diabetes treatment. They provide a platform for patients to receive expert education and support regarding diabetes management. Their modern factory in Macierzysz, near Warsaw, is equipped with advanced technology for the synthesis and production of insulin.

Registered address
ul. Poznańska 12, 05-850 Macierzysz, Poland
Website
Email
Phone
Social media
Electronic delivery address
AE:PL-71202-20543-DWAJJ-27

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 33 days early. All were audited by a statutory auditor.

  • 202529/06/2026
  • 202427/06/2025
  • 202317/06/2024
  • 202222/06/2023
  • 202107/07/2022
  • 202001/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Sanctions and PEP lists

PersonList
Beata Anna StelmachCzłonek organu spółki Skarbu Państwa
Waldemar Piotr DąbrowskiMinister kultury i dziedzictwa narodowego
Wiesław Waldemar WalendziakPoseł na Sejm Rzeczypospolitej Polskiej
Wojciech Michał Raduchowski-BrochwiczCzłonek organu spółki Skarbu Państwa

Stock quotes

PLN 3.45
+0.01 (+0.29%)
3.423.443.463.4510:0012:0014:0016:00
Open
PLN 3.44
High
PLN 3.46
Low
PLN 3.41
Volume
61.66K
Avg. vol.
19.03K
Market cap
PLN 295.8M
P/E ratio
–
EPS
-PLN 26.82
Shares outstanding
85.86M
52-week
PLN 3.34 – 3.54
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 17.53mUSD 2.07mUSD 280.39k
Q2 2026USD 19.19mUSD -2.80mUSD -2.48m
Q1 2026USD 13.27mUSD -1.09mUSD -1.39m
Q4 2025USD 16.17mUSD 967.86kUSD 442.49k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing1,002 / 24,548
Top 4.1%
City · Macierzysz3 / 54
Top 5.6%
Voivodeship · Mazowieckie1,117 / 76,892
Top 1.4%
Country · Poland3,219 / 297,069
Top 1.1%

Results vs industry

Revenue
This companyUSD 71.78mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD 852.08kMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 67.33mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 192.00mMedianUSD 897.46kAverageUSD 31.52m

Offer

  • Insulin
  • Antidiabetic medicines
  • Medical devices
  • Injection systems
  • Diabetes care solutions
Certifications: GMP, ISO 13485

Websites

The sites are available in: Polish and English.

  • bioton.comBIOTON – dostawca kompletnych rozwiązań diabetologicznych
    WordPressGoogle Tag ManagerYoast SEONginx
  • biotonweb.plBIOTON – dostawca kompleksowych rozwiązań dla badań nad cukrzycą – rozwiązania dla biotechnologicznego procesu produkcji leków, od DNA po gotowy produkt leczniczy
    WordPress 7.1Elementor

Trademarks

The company holds 77 active trademarks registered with the Polish Patent Office. 35 marks have expired or were not registered. The first mark was filed in 1993.

MarkNumberClassesStatusProtected until
Gensucare v (word)Z.5372635, 10Protected Dec 2, 2031
Combodiab (word)Z.5029225, 10Protected Jul 30, 2029
Depediab (word)Z.5029215, 10Protected Jul 30, 2029
BIOTON Z.4843691, 3, 5, 10, 35, 36, 37, 39, 40, 41, 42, 44, 45Protected Apr 3, 2028
GensuFine (word)Z.4749465, 10Protected Aug 3, 2027
MarkProtected until
Gensucare v (word)Dec 2, 2031
Combodiab (word)Jul 30, 2029
Depediab (word)Jul 30, 2029
BIOTON Apr 3, 2028
GensuFine (word)Aug 3, 2027

Job offers

The company has its own careers page: bioton.com/kariera.

Authorized Representatives

Romuald Apollo Harwas age 54 – Management Board Member
Kamila Helena Muśnicka age 47 – Attorney-in-fact (joint)
Jeremy James Launders – President of the Management Board

Manner of representation

If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.

Supervisory board

Nicola Cadei – Supervisory Board Member
Yun Song Cun – Supervisory Board Member
Dariusz Roman Trzeciak age 59 – Supervisory Board Member
Rafał Paweł Deja age 60 – Supervisory Board Member
Wei Fan – Supervisory Board Member

Beneficial owners

Bioton is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Capital group

NameOwnership
Informacje ogólne o Biolek Sp. z o.o.
10%
PODSTAWOWE INFORMACJE DOTYCZĄCE SPÓŁKI ORAZ GRUPY KAPITAŁOWEJ BIOTON S.A.
9%
Skład Zarządu i Rady Nadzorczej Bioton S.A.
9%

Bank accounts

Registered as a VAT taxpayer on 1993-07-05.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Apr 28, 2026Call to creditors

Public aid

10 public aid cases recorded, with a total value of $9,080,083.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine
–
Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine
–

European Funds

ProjectEU co-financing
Development of an innovative technology for producing short- and long-acting insulin analogues for use in diabetes therapy.
$5.3M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Change history

DateEvent
2026-08-21Share capital reduction
2026-07-21PKD change
2026-04-27Address change
2019-11-25PKD change
2015-07-09PKD change

FAQ

Last updated: 2026-10-03